Fludeoxyglucose (18F)
- Generic Name
- Fludeoxyglucose (18F)
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H11FO5
- CAS Number
- 63503-12-8
- Unique Ingredient Identifier
- 0Z5B2CJX4D
- Background
Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection.
- Indication
The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism.
...
- Associated Conditions
- Cancer, Coronary Artery Disease (CAD), Epileptic seizure, Left Ventricular Dysfunction
- Associated Therapies
- -
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 138
- Registration Number
- NCT01507428
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 1
- Registration Number
- NCT01494012
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.